BURGWEDEL, Germany, Oct. 29, 2018 /PRNewswire/ -- MYR Pharma today announced that the results of 48 weeks of administrationof Myrcludex, MYR`s first-in-class entry inhibitor for treatment of hepatitis B and D infection, will be presented at the Presidential Plenary Session of the upcoming AASLD meeting in San Francisco:
"I am looking forward to share the encouraging results of this study at this very important meeting", said Heiner Wedemeyer, MD, Professor at Essen University Medical School and Chairman of MYR`s Clinical Advisory Board.
About Myrcludex Myrcludex is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the HBV receptor on the hepatocyte surface and prevents the infection of healthy cells and viral spreading within the liver. Myrcludex has received Orphan Designation for treatment of HDV infection from EMA and FDA, PRIME scheme eligibility from EMA, and a breakthrough therapy designation from FDA.
About MYR PharmaMYR Pharma is a German clinical stage biotechnology company focused on drugs for the treatment of chronic hepatitis B and D virus infections. The company`s lead compound is currently progressing into Phase 3 studies in the indication chronic HDV infection.
Media Contact: Alexey Eliseev, 1-617-953-0767
View original content:http://www.prnewswire.com/news-releases/myr-pharma-announces-presentation-of-interim-results-of-myr-203-a-phase-2-study-of-myrcludex-in-combination-with-pegylated-interferon-in-chronic-hepatitis-delta-300739264.html
SOURCE MYR Pharma
Subscribe to our Free Newsletters!